2. Academic Validation
  3. Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia

Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia

  • Eur J Med Chem. 2025 Oct 15:296:117893. doi: 10.1016/j.ejmech.2025.117893.
Yu Yang 1,  Qian Yao 1,  Dan Song 1,  Kexin Tang 2,  Zijun Tang 3,  Mingxing Hu 4,  Yi Luo 5,  Yongmei Xie 6
Affiliations

Affiliations

  • 1 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China.
  • 2 Department of Biology, Emory University, Atlanta, 30322, USA.
  • 3 Medical School of Guangxi University, Guangxi Key Laboratory of Special Biomedicine, Nanning, 530004, China.
  • 4 Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: hmx1990@scu.edu.cn.
  • 5 Department of Orthopedics and Orthopaedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: orthop_luoyi@163.com.
  • 6 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China. Electronic address: xieym@scu.edu.cn.
PMID: 40578254 DOI: 10.1016/j.ejmech.2025.117893
Abstract

Fms-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase expressed in hematopoietic progenitor cells and in most AML cell lines. Pharmacological inhibition of FLT3 enzymatic function is now a well-established strategy for the treatment of patients with these malignancies. Herein, we report the discovery and characterization of a FLT3 degrader A2. By design, A2 also mediates the degradation of transcription factors GSPT1 and IKZF1/3 through molecular glue interactions with the Cereblon E3 ubiquitin Ligase complex. Importantly, A2 exhibited significantly enhanced antiproliferative activity against drug-resistant AML cells compared to Gilteritinib (MV-4-11: IC50 = 1.67 ± 0.14 nM vs IC50 = 6.52 ± 1.20 nM). Furthermore, A2 with the rigid linker demonstrated improved some pharmacokinetic properties such as half-life (T1/2), which were achieved through rational design. Overall, A2 achieves concurrent degradation of these proteins by functioning as both PROTAC and molecular glue.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z